A new investigational drug called buntanetap is showing early promise in slowing cognitive decline in Parkinson's disease patients, with trial data suggesting it may help preserve thinking and memory skills that typically deteriorate as the disease progresses. In a 6-month clinical trial involving people with early Parkinson's disease, patients taking buntanetap at a 10 milligram dose showed an average improvement of 0.65 units on cognitive function tests, while those receiving placebo experienced a decline of 0.50 units. This finding represents a meaningful shift in how researchers are approaching Parkinson's treatment, moving beyond just managing movement symptoms to address the cognitive changes that significantly impact quality of life.

Why Cognitive Decline in Parkinson's Matters More Than Many Realize?

Parkinson's disease is widely known for causing tremors, stiffness, and movement difficulties. However, many patients and even some doctors underestimate how profoundly the disease affects thinking, memory, and daily decision-making. These non-motor symptoms can be just as disabling as physical tremors, yet they often receive less attention in treatment planning. Buntanetap's potential to address cognitive decline represents a shift in how neurologists are thinking about comprehensive Parkinson's care. The drug is being developed by Annovis Bio Inc. and is taken as a once-daily capsule. Clinical research has enrolled a combined 2,134 participants across four trials, with the first beginning in 2022 and the latest projected to conclude in late 2025.

What Do the Early Trial Results Actually Show?

The most compelling data comes from a double-blind study comparing buntanetap to placebo in early Parkinson's disease patients over 6 months. Researchers measured cognitive function using the Mini-Mental State Examination (MMSE), a standard test where higher scores indicate better thinking and memory. Among participants with baseline MMSE scores between 20 and 28, those taking the 10 milligram dose of buntanetap improved by an average of 0.65 units, while the 20 milligram dose improved by 0.45 units. In contrast, placebo participants declined by 0.50 units on average. While these numbers might seem modest, they represent the difference between cognitive stability and decline over just six months, which is significant in a progressive neurological disease.

The same trial also measured motor symptoms using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), which tracks movement quality and control. All treatment groups showed improvement in motor symptoms, with the 20 milligram dose of buntanetap reducing motor symptom scores by an average of 2.66 units compared to 2.90 units for placebo. For activities of daily living, the 20 milligram dose showed minimal change, while the 10 milligram dose showed a slight worsening of 0.57 units, suggesting that optimal dosing may vary depending on which symptoms are most important to address.

How Does Buntanetap Work, and What Are the Side Effects?

The exact mechanism of how buntanetap works in the brain is still being studied, but clinical trials are exploring its potential effects on both Parkinson's disease and Alzheimer's disease, suggesting it may influence multiple neurological pathways. The medication is administered as vegetarian capsules containing hydroxypropyl methylcellulose (HPMC), taken once daily in doses ranging from 7.5 to 30 milligrams depending on the condition being treated.

In clinical trials, buntanetap was generally well tolerated, with side effects occurring at rates only slightly higher than placebo. The most commonly reported side effects included nausea in 4.6% of patients taking buntanetap compared to 2.8% on placebo, fatigue in 4.0% versus 2.8%, and dizziness in 2.7% versus 1.1%. These mild side effects suggest the drug has a favorable safety profile compared to some existing Parkinson's medications, which can cause more significant adverse effects.

Steps to Understanding Your Treatment Options for Parkinson's Cognitive Decline

• Discuss Non-Motor Symptoms: Talk with your neurologist about cognitive changes you've noticed, including memory problems, difficulty concentrating, or slower thinking speed. Many patients don't realize these are part of Parkinson's disease and don't mention them.
• Ask About Clinical Trials: If you have early Parkinson's disease, inquire whether you might be eligible for ongoing trials of buntanetap or other emerging treatments. Clinical trials often provide access to cutting-edge therapies before they become widely available.
• Evaluate Your Current Treatment Plan: Work with your neurologist to assess whether your current medications are adequately addressing both motor and non-motor symptoms. Treatment plans may need adjustment as the disease progresses.
• Consider Multidisciplinary Care: Seek treatment from neurologists who work within teams that include physiotherapists, occupational therapists, and mental health professionals, as this integrated approach addresses the full spectrum of Parkinson's symptoms.

How Does This Fit Into the Broader Movement Disorder Treatment Landscape?

Buntanetap represents one of several emerging approaches to movement disorders that extend beyond traditional dopamine-based medications. Movement disorders like Parkinson's disease, dystonia, and essential tremor have historically been treated with drugs that increase dopamine levels in the brain or with deep brain stimulation, a surgical procedure that uses electrical impulses to regulate abnormal brain activity. However, these approaches don't always address cognitive decline effectively, which is why researchers are exploring new mechanisms of action.

The best neurologists treating movement disorders today operate within multidisciplinary environments where specialists collaborate across disciplines, combining pharmacological therapies, rehabilitation, and advanced surgical interventions tailored to each patient's specific needs. This comprehensive approach recognizes that movement disorders involve both motor symptoms like tremors and stiffness, as well as non-motor symptoms including cognitive changes, sleep disturbances, and emotional health concerns. Buntanetap's potential to address cognitive decline fits squarely within this evolving model of personalized, comprehensive care.

Ongoing research continues to expand treatment possibilities. A Phase 2/3 trial is currently recruiting participants to evaluate the long-term safety of buntanetap in Parkinson's disease over 36 months, suggesting that researchers are confident enough in early results to pursue larger, longer-term studies. Additionally, one trial is exploring how buntanetap might work alongside deep brain stimulation, investigating whether the drug could enhance outcomes for patients who have undergone this surgical procedure.

For patients living with Parkinson's disease, particularly those in early stages, these developments offer hope that future treatment options may better address the full range of symptoms that impact daily life. The shift toward treating cognitive decline alongside movement problems reflects a maturing understanding of Parkinson's as a complex disease requiring equally complex, personalized treatment strategies.